Margaux Gardet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margaux Gardet has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Carlos de la Calle-Fabregat
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
4 shared publications - Charles-Antoine Dutertre
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
4 shared publications - Florent Ginhoux
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
4 shared publications - Kevin Mulder
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
4 shared publications Ahmed-Amine Anzali
INSERM U1015, Gustave Roussy, Paris-Saclay University, Villejuif, France
3 shared publications- Alexander Swarbrick
Cancer Ecosystems Program, Garvan Institute of Medical Research, Darlinghurst, Australia
3 shared publications
Latest Publications
- Open Access
- 20 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 636
Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues
- 20 January 2026
- Published by Springer Nature in Nature Immunology
- Vol. 27 (3) , 636
Open AccessAuthor Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues
- Open Access
- 16 December 2025
- Published by Springer Nature in Nature Immunology
- Vol. 27 (1) , 167
Author Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues
- 16 December 2025
- Published by Springer Nature in Nature Immunology
- Vol. 27 (1) , 167
Open AccessAuthor Correction: DC subsets and states unraveled across human juxtatumoral and malignant tissues
- 8 December 2025
- Published by Springer Nature in Nature Immunology
- Vol. 27 (1) , 135-149
DC subsets and states unraveled across human juxtatumoral and malignant tissues
Dendritic cells (DCs) are professional antigen-presenting cells. While plasmacytoid DCs (pDCs) are poor antigen-presenting cells at steady state, myeloid DCs (mDCs), which include DC1s, DC2s and DC3s, are specialized in T cell priming. To generate unbiased human DC atlases, we integrated DCs from 13 tumor tissues across 40 datasets to create a pDC + mDC-VERSE (DC-VERSE) and an mDC-VERSE single-cell RNA-sequencing compendium. We characterized DC subsets and ‘states’ across these tissues. Most studied tumors contained CD207+ DCs, a subset of CD1c+ DCs, whose expansion inversely correlated with tumor CD8+ resident memory T cells, T cell clonality and the survival of patients treated with immune checkpoint inhibitors. Similarly to CCR7+ mDCs (a common state of DC1s, DC2s and DC3s), we found that CD207+ DCs were a common state of DC2s and DC3s. Spatially resolved single-cell transcriptomic and immunohistofluorescence analyses of human carcinomas demonstrated that lymphocytes and most DCs were enriched within the tumor stroma, while CD207+ DCs were mostly embedded within tumor nests. These DC-VERSEs provide a robust resource available to the scientific community on DCs in health and pathology.
- 8 December 2025
- Published by Springer Nature in Nature Immunology
- Vol. 27 (1) , 135-149
DC subsets and states unraveled across human juxtatumoral and malignant tissues
Dendritic cells (DCs) are professional antigen-presenting cells. While plasmacytoid DCs (pDCs) are poor antigen-presenting cells at steady state, myeloid DCs (mDCs), which include DC1s, DC2s and DC3s, are specialized in T cell priming. To generate unbiased human DC atlases, we integrated DCs from 13 tumor tissues across 40 datasets to create a pDC + mDC-VERSE (DC-VERSE) and an mDC-VERSE single-cell RNA-sequencing compendium. We characterized DC subsets and ‘states’ across these tissues. Most studied tumors contained CD207+ DCs, a subset of CD1c+ DCs, whose expansion inversely correlated with tumor CD8+ resident memory T cells, T cell clonality and the survival of patients treated with immune checkpoint inhibitors. Similarly to CCR7+ mDCs (a common state of DC1s, DC2s and DC3s), we found that CD207+ DCs were a common state of DC2s and DC3s. Spatially resolved single-cell transcriptomic and immunohistofluorescence analyses of human carcinomas demonstrated that lymphocytes and most DCs were enriched within the tumor stroma, while CD207+ DCs were mostly embedded within tumor nests. These DC-VERSEs provide a robust resource available to the scientific community on DCs in health and pathology.
- Open Access
- 20 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (38) , eadq5226
NF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment
Macrophages orchestrate tissue homeostasis and immunity. In the tumor microenvironment (TME), macrophage presence is largely associated with poor prognosis because of their reprogramming into immunosuppressive cells. We investigated the effects of hypoxia, a TME-associated feature, on the functional, epigenetic, and transcriptional reprogramming of macrophages and found that hypoxia boosts their immunogenicity. Hypoxic inflammatory macrophages are characterized by a cluster of proinflammatory genes undergoing ten-eleven translocation–mediated DNA demethylation and overexpression. These genes are regulated by NF-κB, while HIF1α dominates the transcriptional reprogramming, demonstrated through ChIP-seq and pharmacological inhibition. In bladder and ovarian carcinomas, hypoxic inflammatory macrophages are enriched in immune-infiltrated tumors, correlating with better patient prognoses. Coculture assays and cell-cell communication analyses support that hypoxic-activated macrophages enhance T cell–mediated responses. The NF-κB–associated hypomethylation signature is displayed by a subset of hypoxic inflammatory macrophages, isolated from ovarian tumors. Our results challenge paradigms regarding the effects of hypoxia on macrophages and highlight actionable target cells to modulate anticancer immune responses.
- 20 September 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (38) , eadq5226
Open AccessNF-κB and TET2 promote macrophage reprogramming in hypoxia that overrides the immunosuppressive effects of the tumor microenvironment
Macrophages orchestrate tissue homeostasis and immunity. In the tumor microenvironment (TME), macrophage presence is largely associated with poor prognosis because of their reprogramming into immunosuppressive cells. We investigated the effects of hypoxia, a TME-associated feature, on the functional, epigenetic, and transcriptional reprogramming of macrophages and found that hypoxia boosts their immunogenicity. Hypoxic inflammatory macrophages are characterized by a cluster of proinflammatory genes undergoing ten-eleven translocation–mediated DNA demethylation and overexpression. These genes are regulated by NF-κB, while HIF1α dominates the transcriptional reprogramming, demonstrated through ChIP-seq and pharmacological inhibition. In bladder and ovarian carcinomas, hypoxic inflammatory macrophages are enriched in immune-infiltrated tumors, correlating with better patient prognoses. Coculture assays and cell-cell communication analyses support that hypoxic-activated macrophages enhance T cell–mediated responses. The NF-κB–associated hypomethylation signature is displayed by a subset of hypoxic inflammatory macrophages, isolated from ovarian tumors. Our results challenge paradigms regarding the effects of hypoxia on macrophages and highlight actionable target cells to modulate anticancer immune responses.